chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Moderna monovalent dose #3 given in stead of bivalent dose. As of today, 2/8/23, there have been no reports of adverse reaction from parents/guardian.
pt recvd vax; 5 min p/ vax, became nauseated; felt bad all over;3 hrs later high T; flu sxs, body aches; T 105.1 in er;
Information has been received from a registered nurse concerning an 8 year old male who on 31-OCT-2007 was vaccinated with ZOSTAVAX (Lot #658086/0761U) instead of VARIVAX.  The nurse indicated that he grabbed the wrong vial in the freezer.  The patient will be re-vaccinated in 30 days with VARIVAX.  It was further reported that ZOSTAVAX and VARIVAX are no longer stored near each other in the freezer, and the labels were made more visible to prevent any reoccurrences.  Additional information is not expected.
High blood pressure; up and down heart rate; Dry mouth; Taste of Salt; This spontaneous case was reported by a consumer and describes the occurrence of HYPERTENSION (High blood pressure), PALPITATIONS (up and down heart rate), DRY MOUTH (Dry mouth) and DYSGEUSIA (Taste of Salt) in a 78-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 15-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-Feb-2021, the patient experienced HYPERTENSION (High blood pressure), PALPITATIONS (up and down heart rate), DRY MOUTH (Dry mouth) and DYSGEUSIA (Taste of Salt). At the time of the report, HYPERTENSION (High blood pressure), PALPITATIONS (up and down heart rate) and DRY MOUTH (Dry mouth) had not resolved and DYSGEUSIA (Taste of Salt) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were provided.  No treatment information provided.   This case was linked to US-MODERNATX, INC.-MOD-2021-101121 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-101121:
Patient started within 6 hours having joint pain and chills.  Chills lasted about 5 hours, but joint pain in all joints on left side of the body never left and is still present currently.
After receiving the first dose of the Covid vaccination, I had Amenorrhea for three months. I have had regular menstruation since I was 11 years old and have never missed a period prior to receiving the Covid vaccine. When I finally started my period again in April, it was the heaviest period I have ever experienced. It lasted for 4 days and was shockingly heavy for all 4 days.
As soon as I was injected, my tongue got numb. I told the nurse. About a half  hour later that stopped, but numbness went into my right cheek. Felt like after you go to dentist. That lasted a few hours. Then I was fine.
Moderna COVID-19 Vaccine EUA Red rash at injection site about 2 inches in diameter lasting about 12 days.  Resolved by day 13 following vaccination.
Slept all day the following next day.  Second day I woke up with fever blisters covering my mouth and inside my nose.
Mild rash at first starting on limbs, then proceeding to abdomen and face. By third day, rash became moderate in severity.
Client received CanSino COVID vaccine outside of the US, no reaction. CanSino vaccine not approved by World Health Organization, Janssen given as an alternative on 09/15/21.
Heart pain. When I moved side by side the pain was worse. I wasn't able to perform my physical exercises routine.
cough; cold sweat; fatigue; fever; severe headaches; loss of taste; joint and muscle pain; joint and muscle pain; This is a spontaneous report from a contactable consumer.  An elderly male patient received the bnt162b2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE; Lot Number: EL8982), via an unspecified route of administration on 22Jan2021 14:30 at a single dose for COVID-19 immunization. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Medical history included blood pressure high (HBP), diabetic; both from an unknown date and unknown if ongoing. Concomitant medications included unspecified medications taken for an unspecified indication from an unspecified date to an unspecified date; taken within two weeks of vaccination. The patient had no allergies to medications, food, or other products. On 26Jan2021, the patient experienced: cough (non-serious), cold sweat (non-serious), fatigue (non-serious), fever (non-serious), severe headaches (non-serious), loss of taste (non-serious), joint and muscle pain (non-serious); which resulted in a doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of cough, cold sweat, fatigue, fever, severe headaches, loss of taste, joint and muscle pain; which included unspecified cough medications, nausea medications and paracetamol (TYLENOL). The clinical outcome of the events was not recovered. Since the vaccination, the patient has not been tested for COVID-19.
Golf ball size swelling at injection site. Area is pink, "strange texture" "dry skin" warm to touch, itching at times. No fever. Referred her to ordering physician.
Sudden onset of tinnitus which has not resolved in the ensuing 4 weeks.   It is constant (24/7).  High pitched ringing is present in both ears.  Though constant it could be considered 'mild' in intensity,  It Does not interfere with hearing other things.
p/vax pt describes tension as if calf muscles are flexed behind both knees & extending down to both calves;no pain involved;feels as if is standing on toes;
The patient had injection-site reaction. The injeciton-site reaction was small, quarter-sized, raised, red and warm to touch; The patient described injection side as sore but not painful; The patient had injection-site reaction. The injeciton-site reaction was small, quarter-sized, raised, red and warm to touch; This spontaneous report has been received from a registered nurse concerning a 16-year-old non-pregnant female patient.  The patient's concurrent condition included allergy to dairy. The patient had no other pertinent medical history, previously drug reactions, or concomitant medications.  On 28-FEB-2019, the patient received the first dose of HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast) (GARDASIL 9) (strength, dose, route of administration and anatomical location were not provided) (lot # 1581027, expiration date: 03-JUN-2021) (indication reported as vaccine).  It was reported that on 01-MAR-2019 (reported as one day after the vaccine administration), the patient experienced an injection site reaction. The injection-site reaction was small, quarter-sized, raised, red and warm to touch; the patient also described injection site as sore but not painful (injection site erythema) (injection site pain) (injection site warmth). On approximately 08-MAR-2019 (reported as: one week later), the patient recovered from all the events. The patient did not received treatment for the events and did not seek medical attention.  The causal relationship between the aforementioned adverse events and the HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast) (GARDASIL 9) was unknown.
Pt states neck got "really tight" in lower neck, unable to turn neck left to right, prohibited from standing up straight, head feels like a lot of pressure, feels dehydrated, pt feels really hot, possibly feverish. Has taken Ibuprofen, but has not had any relief.
Pt devel inc t103, swelling both thighs, seen in ER given APAP w/codiene;
In February, 2002, the vaccinee received her 1st injection of Engerix-B. Two days, post vax, she experienced bruising at the injection site measuring 2" in diameter. As of 2/27/02, the bruise was resolving, but still present. The reporter considered the event to be probably related to Engerix-B administration.
Fever; chills; pain at injection site; headaches; muscle pains; joint pains; nausea; vomiting; feeling unwell; This is a spontaneous report from a contactable consumer, the patient. A 63-year-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: ER8730), via an unspecified route of administration on the right arm on 20Mar2021 at 15:00 (at the age of 63-year-old), as an unknown single dose for COVID-19 immunisation. Medical history included hypertension and colon cancer. Concomitant medications were not reported. The patient did not have any allergies to medications, food or other products. Prior to vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 21Mar2021 at 1300, the patient experienced fever, chills, pain at injection site, headaches, muscle pains, joint pains, nausea, vomiting and feeling unwell. The patient received other medication within two weeks of vaccination. Tylenol and Motrin was taken as therapeutic measures as a result of adverse events. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events fever, chills, pain at injection site, headaches, muscle pains, joint pains, nausea, vomiting and feeling unwell was resolved on an unknown date.   No follow-up attempts are needed. No further information is expected.
Just the mild side effects, but some were really intense. Crazy chills, body aches, joint pain, stiff muscles, fever, hot flashes, headache, vomiting. I only vomited day 2. The chills and body aches were day 1 and 2. The fever, stiff muscles, hot flashes were days 1, 2, 3 and 4. The headaches were days 3, 4 and 5 (today.) No insurance, so no doctor visit. Treated with a ton of sleep and an appropriate amount of fluids. Just reporting for science or whatever. Thanks!
Patient received second dose of vaccine too early. First dose was received 12/29/2020 and second dose was received on 01/19/2021.
confusion; change in mental status; This spontaneous case was reported by an other health care professional and describes the occurrence of CONFUSIONAL STATE (confusion) and MENTAL STATUS CHANGES (change in mental status) in an 88-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 10-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Feb-2021, the patient experienced CONFUSIONAL STATE (confusion) and MENTAL STATUS CHANGES (change in mental status). At the time of the report, CONFUSIONAL STATE (confusion) and MENTAL STATUS CHANGES (change in mental status) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant medications were not provided. Treatment information was not reported.
I received my vaccine on 4/20/2021 and almost immediately I began to fee the vaccine go into my body, shortly after I started feeling extremely dizzy and fatigued and my vision became spotty, I knew I needed to get off the road, I had to call my neighbor to come and pick me up. As I waited for my ride, I started getting a really bad headache, I took Excedrin which did not help, it got really worse, so I took my migraine medicine Reyvow 50mg and it did not do anything for the headache and it typically does. I messaged my neurologist asking what I should do and he told me to take Maxalt 10mg- which did not help either. Then I took 2 Tylenol and then went to lay down. I took my temperature and it was normal. I rested for 6 to 7 hours. I still felt tired and my muscles were hurting really badly and I was extremely weak. I developed a rash on my legs - only the tops of my legs. These symptoms are ongoing still to this date, just more mild that what they had been previously. I also developed some breathing and heart issues, which I am still being tested for.
This is a spontaneous report from a Pfizer sponsored program. A contactable female consumer (patient) of an unspecified age received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Batch/Lot number was not reported), via an unspecified route of administration on an unspecified date as single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. It was reported that patient got first dose of the vaccine and experiencing pain on half of her face and wanted to know if that was okay. There was no any unaddressed medical questions referred or forwarded to Medical Information. The outcome of event was unknown.  No Follow-up attempts are needed; information about lot/batch number cannot be obtained.
Acute back pain, numbness and tingling in legs 2-3 weeks after dose administered.  After 3  ED visits was admitted to acute inpatient PT to return to walking, did need IV steroids and close follow-up with neurology. Diagnosis differential MS, vs Tranversemyelitis, now Guillain-Barré ?
fever; This case was reported by a consumer via call center representative and described the occurrence of fever in a elderly female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 30th May 2019, the patient received the 1st dose of Shingrix. On 30th May 2019, less than a day after receiving Shingrix, the patient experienced fever. On an unknown date, the outcome of the fever was recovering/resolving.   It was unknown if the reporter considered the fever to be related to Shingrix.  Additional details were reported as follows: The age at vaccination was not reported. The reporter did not consent to follow up. Limited information was provided.
02/01/2019 were DTap, Meningococcal, and HPV. On morning of 02/02/2019 became extremely aggressive and oppositional. Anxiety. Constant crying. Inconsolable. Flailing body. Took one hour restrain him to lay down. Injection site and arm pain. Inflammation in brain and body. Loss of appetite, OCD type behavior. Has a history of possible PANDAS and this reaction mimicked the symptoms of when he gets Strep and inflammation in the brain. He has not been himself since for the past few weeks.
Patient was sitting in waiting room after she received the 2 vaccines. Shortly after, patient's  friend screamed for help bc patient fainted. I rushed out; patient was conscious again by the time I got to patient. Pt denied SOB . Just the tips of her fingers were slightly tingling,  but resolved shortly after. Patient denied for us to call the ambulance.  Drank water and waited until she felt better and back to " normal" before she left.
Due to the snow, I took the bus to the HD, instead of riding bicycle.  Due to the snow, however, buses were reduced, only running hourly; I walked home using my walking sticks instead of waiting for the next bus.  Later in the evening, I developed an extremely severe right shin splint (anterior tibialis irritation).  My left leg is always painful, even with my  brace that treats me like an amputee.  Dr at the Clinic has told me that he's amazed I'm still able to walk, even with my custom brace. Beginning about 11 PM on 2/11/2021, my legs were so painful that I could not stand and walk, even wearing my brace.  Crawling was painful too, but I crawled anyhow.  I also scooted on my butt and grabbed furniture to get around.  Getting into bed took a very long time, quite likely several hours, due to my severely impaired mobility.  My bed is low, several inches above the ground; I had to knowingly fall into bed to get there.  Once in bed, I was still in lots of pain.
received by error a Shingrix third dose; This case was reported by a nurse via call center representative and described the occurrence of extra dose administered in a patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 2 doses on an unknown date). Concurrent medical conditions included immunocompromised.   On 1st December 2022, the patient received the 3rd dose of Shingrix. On 1st December 2022, unknown after receiving Shingrix, the patient experienced extra dose administered. On an unknown date, the outcome of the extra dose administered was unknown.   Additional Information: GSK receipt date: 1-Dec-2022 Reporter's comment: The reporter had not provided permission to storage personal information in medical information database.  Data was sent to safety via email. The reporter consented to follow-up via email. Additional supportive information: The patient received third dose of Shingrix, which led to extra dose administered.
Pt received the Moderna COVID19 vaccine and as soon as she sat down in observation she alerted the staff she was feeling itchy all over her body. EMS on scene and evaluated the pt. Rash developed on pt's back. Pt transported to Hospital.
weak arm/pain/couldn't move, chills, fever, headache, lips swollen, face pain when touching, huge pouch under eyes/cheeks sore, hoarse
NOTICED RED, RAISED RASH ON FACE AROUND MOUTH, CHEST, AND ABDOMEN.  PATIENT OTHERWISE APPEARED HIS NORMAL SELF AND THE RASH DID NOT SEEM TO BOTHER HIM.
current age 9; Dose 1 15NoV2021; headache; high fevers; stomach upset; nausea; rash; unable to keep anything down; muscle aches; body aches; This is a spontaneous report received from contactable reporter(s) (Physician). The reporter is the parent.  A 9 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), intramuscular, administered in arm left, administration date 15Nov2021 12:30 (Batch/Lot number: unknown) at the age of 9 years as dose 1, single for covid-19 immunisation; influenza vaccine (INFLUENZA), administration date 15Nov2021 12:30 (Batch/Lot number: unknown). The patient had no relevant medical history. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: HEADACHE (non-serious) with onset 15Nov2021, outcome "recovering", described as "headache"; PYREXIA (non-serious) with onset 15Nov2021, outcome "recovering", described as "high fevers"; ABDOMINAL DISCOMFORT (non-serious) with onset 15Nov2021, outcome "recovering", described as "stomach upset"; NAUSEA (non-serious) with onset 15Nov2021, outcome "recovering", described as "nausea"; RASH (non-serious) with onset 15Nov2021, outcome "recovering", described as "rash"; EATING DISORDER (non-serious) with onset 15Nov2021, outcome "recovering", described as "unable to keep anything down"; MYALGIA (non-serious) with onset 15Nov2021, outcome "recovering", described as "muscle aches"; PAIN (non-serious) with onset 15Nov2021, outcome "recovering", described as "body aches"; PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (non-serious) with onset 15Nov2021 12:30, outcome "unknown", described as "current age 9; Dose 1 15NoV2021". The events "headache", "high fevers", "stomach upset", "nausea", "rash", "unable to keep anything down", "muscle aches", "body aches" and "current age 9; dose 1 15nov2021" were evaluated at the physician office visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of headache, pyrexia, abdominal discomfort, nausea, rash, eating disorder, myalgia, pain.  Clinical course: Started having high fevers, stomach upset, nausea, unable to keep any-thing down, rash, ongoing for 4 days. Also has muscle aches, body aches, headache. The patient did not receive treatment for adverse event. Covid prior vaccination was reported as 'No''. Covid tested post vaccination was reported as 'Yes''. Covid test post vaccination. Covid test type post vaccination=Nasal Swab, Covid test name post vaccination=Rt-PCR, covid test date=18Nov2021, Covid test result=Negative. Known allergies : No. Device timestamp 18Nov2021.  Additional information: Seriousness criteria-results in death: No. Seriousness criteria-life threatening: No. Seriousness criteria- caused/prolonged hospitalization: No. Seriousness criteria- disabling/incapacitating: No. Seriousness criteria-congenital anomaly/birth defect: No. Patient did not receive other vaccine in four weeks. Other medications in two weeks:  Received Flu vaccine at the same time.  The lot number for bnt162b2 was not provided and will be requested during follow up.
Information has been received from a certified medical assistant concerning a 12 month old male with no pertinent medical history or drug allergies who on 12-SEP-2007 was vaccinated SC with a 0.5 ml dose of PROQUAD, VARIVAX (lot# 658185/0788U).  Suspect vaccination administered on that same day included a dose of COMVAX.  Concomitant vaccination also administered that day included a dose of poliovirus vaccine inactivated (unspecified).  On 21-SEP-2007 the patient experienced a febrile seizure and was evaluated in the emergency room.  The seizure lasted about 30 seconds.  The patient was not admitted to the hospital, but was seen later that same day in the physician's office.  Subsequently, the patient recovered.  There was no product quality complaint.  Febrile seizure was considered to be disabling by the reporter.  Additional information has been requested.
Systemic: Seizure-Severe, Systemic: Shakiness-Severe, Additional Details: patient had severe seizure few minutes after vaccine which lasted for about a minute and was bleeeding from the mouth. mucus also were coming out from the mouth . no breathing problems, called and EMS came and took him to the hospital
Begining on 10/12 I began feeling a tingling on left eyelid.  The following 2 day developed small lesions.  I had had a previous Shingles outbreak in the same area years before with significan post heptic pain.  I was traveling but went to an urgent care clinic as advised by my home  physician.  I was positively diagnosed with shinlges and given Valacyclovir.
Dizziness for 1 day, body temperature 37.0 degrees Celsius.
The pharmacist administered the Bexsero with no Health Authority protocol or prescription from the physician.  No adverse effects were reported after the administration but patient should have received Menactra instead.
This is a spontaneous report from a contactable consumer (patient). A 48-year-old male patient received BNT162B2 (Pfizer-BioNTech COVID-19 mRNA vaccine, batch/lot# unknown), at age 48,  via an unspecified route of administration, on Apr 1, 2021, at 08:45, single dose, for COVID-19 immunisation. No reported medical history. The patient did not receive any other medications in two weeks. The patient previously took quinine sulfate for unknown indication on unknown date and experienced drug allergy. Prior to the vaccination, patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On Apr 1, 2021, at 10:00,  one hour after the vaccine, patient experienced itchiness and rash; which lasted for an hour or two. No therapeutic measures taken as a result of the reported events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, patient has not tested for COVID-19. The outcome of itchiness and rash: recovered on Apr 1, 2021. No follow-up attempts needed. Information about lot/batch number cannot be obtained.
Headache, NauseaVomiting, stiff arm, sweats, fatigue Narrative:  stiff arm, sweats, fatigue, headache, nausea; resolved in 36 hours